An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

The composition of encapsulated carbinyl iron salt and a process for preparation thereof. The composition comprises high density particles of carbonyl iron salt in combination with lipids and/or emulsifiers. The invention also relates to composition may additionally contain other minerals or combination of minerals. The composition prevents side effects of the iron and masks metallic taste. Further, the composition provides an improved bioavailability and formulated into various oral delivery forms. This composition is useful in the prevention of iron deficiency anemia.

The composition of encapsulated carbinyl iron salt and a process for preparation thereof. The composition comprises high density particles of carbonyl iron salt in combination with lipids and/or emulsifiers. The invention also relates to composition may additionally contain other minerals or combination of minerals. The composition prevents side effects of the iron and masks metallic taste. Further, the composition provides an improved bioavailability and formulated into various oral delivery forms. This composition is useful in the prevention of iron deficiency anemia.

Described herein are compositions and methods for treating constipation in an individual. In some embodiments, the composition and method for treating constipation comprises providing an individual with a therapeutic that comprises a food item and a laxative.

Present invention discloses particular peptide sequences of formula (I);

(R.sup.1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R.sup.2).sub.(n)   (I) (SEQ ID NO: 1);

wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss.

Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Present invention discloses particular peptide sequences of formula (I);

(R.sup.1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R.sup.2).sub.(n)   (I) (SEQ ID NO: 1);

wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss.

Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Present invention discloses particular peptide sequences of formula (I);

(R.sup.1).sub.(m)-Xaa.sub.1IXaa.sub.2T(Q).sub.(p)(R.sup.2).sub.(n)   (I) (SEQ ID NO: 1);

wherein R.sup.1, m, p, n, Xaa.sub.1, Xaa.sub.2, and R.sup.2 have particular meanings, or pharmaceutically or veterinary acceptable salts of these peptides that are effective in the prevention and/or treatment of mammal hair loss.

Invention also relates to particular topical pharmaceutical, nutraceutical or veterinary compositions with the peptides of formula (I).

Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.